Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag

Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag

Source: 
Endpoints
snippet: 

Japanese drugmaker Takeda has made a big push in recent years to build a hand in oncology, particularly in the next-gen cancer space. One of those candidates, tyrosine kinase inhibitor (TKI) mobocertinib, recently earned the FDA’s interest in a small section of untreated lung cancer patients, but will severe GI side effects be a roadblock?